Sector News

Lubrizol Acquires Particle Sciences

September 9, 2015
Chemical Value Chain

The Lubrizol Corporation announces that it has acquired Particle Sciences, a leading contract drug development and manufacturing organization with a comprehensive suite of services for the formulation, analysis and production of complex drug delivery solutions. Headquartered in Bethlehem, PA, Particle Sciences is a global leader in complex formulations including drug eluting device product development as well as sterile and particulate drug products. This acquisition further expands Lubrizol LifeSciences’ pharmaceutical development capabilities, providing full service drug delivery solutions to the market across a variety of dosage forms.

“With the addition of Particle Sciences and the recent acquisition of Vesta, we are now able to offer customers a complete solution that is one of the most comprehensive in the industry,” stated Deb Langer, vice president and general manager, Lubrizol LifeSciences. “Additionally, the Particle Sciences acquisition allows us to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems for improved patient outcomes.”

Lubrizol LifeSciences has significantly expanded its capabilities through new products, state-of-the-art facilities, acquisitions and alliances. The combination of Lubrizol’s polymer expertise, Vesta’s quality medical manufacturing and Particle Sciences’ leadership in drug formulation development, allows LifeSciences to provide end-to-end solutions for success in the drug delivery market. With this unique combination, Lubrizol LifeSciences delivers comprehensive medical and pharmaceutical solutions, including to the growing combination product market.

“Particle Sciences and Lubrizol LifeSciences have worked together for several years providing various elements of an end-to-end solution from polymer supply through formulation and commercial manufacturing,” said Mark Mitchnick, chief executive officer, Particle Sciences. “With this transaction, Lubrizol LifeSciences acquires Particle Sciences’ extensive formulation, analytic and production assets for drug eluting devices, particulate, sterile and other complex drug products established over the last 10 years. We expect that coordinating all of this under one company will greatly benefit our customers.”

Particle Sciences will now be part of Lubrizol Advanced Materials but will retain its company name. Financial terms of the transaction were not disclosed.

Source: The Lubrizol Corporation

comments closed

Related News

May 21, 2022

Sika opens new manufacturing plant in Bolivia 

Chemical Value Chain

Sika AG (Baar, Switzerland) has opened a new plant in Santa Cruz de la Sierra, thus doubling its production capacity for mortar and concrete admixtures in Bolivia. With this new facility in one of the country’s main industrial agglomerations, Sika is positioning itself for continued growth in the dynamic Bolivian construction market.

May 21, 2022

Chevron increases renewable fuel market share with REG acquisition

Chemical Value Chain

Chevron Corporation (NYSE: CVX) and Renewable Energy Group, Inc. (NASDAQ: REGI) (REG) announced on Monday a definitive agreement under which Chevron will acquire the outstanding shares of REG in an all-cash transaction valued at $3.15 billion, or $61.50 per share.

May 21, 2022

Lotte Chemical to invest $8 bn on hydrogen energy, battery materials by 2030

Chemical Value Chain

Lotte Chemical Corp. will invest 10 trillion won ($8 billion) on hydrogen and battery materials through 2030 to achieve annual revenue of 50 trillion won and carbon neutrality. The Korean chemical producer on Thursday unveiled its new corporate vision outlining key corporate strategies with focus on growth through hydrogen energy and battery materials businesses.